Alamar Biosciences filed for an IPO, seeking to bring its proteomics and immunoassay platform to public markets. The company plans to list on Nasdaq under ticker “ALMR,” and reported revenue momentum supported by product pull-through from its Argo HT instrument. Alamar markets high-sensitivity immunoassay arrays built around its NULISA technology, which uses a two-stage workflow to reduce background signal compared with conventional proximity ligation assays. The company recently launched the NULISAseq Neuro 220 Panel, targeting 220 plasma markers tied to conditions including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. In filings, Alamar stated it aims to pursue FDA clearance for the Argo-HT platform for in vitro diagnostic use, with an expected submission timeline in 2027. Full-year 2025 revenue nearly tripled to $74.2 million, driven by product revenue of $58.4 million and service revenue of $15.8 million.